Pilulka Lékárny has completed an SPO on the START Market of the Prague Stock Exchange
Pilulka Lékárny, a.s. has completed an SPO on the START Market of the Prague Stock Exchange consisting of a capital increase through subscription of new shares. The funds will be used to further develop the company, particularly to strengthen its working capital, to bolster its activities in international markets and to further develop its own e-health solutions.
Since its foundation in 2013, Pilulka has emerged as a leading online pharmacy in central Europe and the operator of a network of franchise and select brick-and-mortar pharmacies in the Czech Republic. Pilulka operates in the Czech Republic, Slovakia and Romania, and entered the Austrian and Hungarian markets in 2022. Pilulka is the number one pharmacy e-shop in-home delivery in the Czech Republic and Slovakia, and among the top three retail pharmacy chains in the Czech Republic.
Oaklins’ team in the Czech Republic acted as an SPO manager in this transaction. The team succeeded in attracting orders from retail investors and high-net-worth individuals.
Talk to the deal team
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth, as well as investing in service quality, innovation and efficiency.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn moreHD Clinical Ltd. has been acquired by NEXUS AG
NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.
Learn more